• FStar

    F-star's transition to a wholly-owned portfolio strategy

    May 2019

  • FStar

    F-star, by CEO Eliot Forster

  • FStar

    Next Generation Bispecifics for Cancer Immunotherapy

    F-star’s goal is to offer cancer patients greater and more durable benefits than current immuno-oncology treatments

  • FStar

    F-star’s Transformation into a Clinical-stage Business

    Informa SCRIP

  • FStar

    Proprietary Pipeline

    F-star generates first- and best-in-class drug candidates that seek to block tumour immune evasion mechanisms

Company Overview

F-star is a clinical-stage biopharmaceutical company developing a proprietary pipeline of disruptive bispecific antibodies for a paradigm-shift in cancer therapy.

Through its tetravalent bispecific antibody (mAb²™) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability.

more about us

statistics

  • $200million raised in non-dilutive capital and revenues
  • $56million raised in venture capital
  • FStar

    Immuno-Oncology

    Immuno-oncology leverages the body’s natural immune response to fight cancer and is currently one the most exciting areas of research within the biopharmaceutical industry with several key drugs on the market and many in late-stage clinical development.

    Read more about our scientific approach
  • FStar

    fcab

    An Fcab is derived from the constant (Fc) region of an antibody - the "stem" of an antibody. Natural antibodies bind antigens via the variable (Fab) regions - the "arms" of an antibody. Our platform introduces new antigen binding sites into the Fc region.

    View all technologies
FStar

Meet the Team

F-star’s leadership team has decades of combined experience from holding senior-level positions in both pharma and biotech and involving the development of dozens of biologics from target selection to clinical trials.

Find out more about our team